KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Artificial intelligence-powered spatial analysis of tumor microenvironment in patients with non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitor.

Yeong Hak Bang, Geun-Ho Park, Jin Woo Oh, Soohyun Hwang, Jun-Gi Jeong, Boram Lee, Cheol Yong Joe, Hyemin Kim, Jinyong Kim, Sehhoon Park, Hyun Ae Jung, Jong-Mu Sun, Jin Seok Ahn, Myung-Ju Ahn, Yoon-La Choi, Chang Ho Ahn, Siraj M Ali, Chan-Young Ock, Se-Hoon Lee

J Immunother Cancer 13(10) e012374

PMID41173494
PMCIDPMC12581073
DOI10.1136/jitc-2025-012374
发表日期2025-10-31
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

PURPOSE: This study evaluated the dynamic changes in the tumor microenvironment (TME) in patients with non-small cell lung cancer (NSCLC) and acquired resistance to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) using an artificial intelligence (AI)-powered spatial TME analyzer. We then assessed the predictive efficacy of immune-checkpoint inhibitors (ICIs)-based treatment. EXPERIMENTAL DESIGN: An AI-powered whole-slide image analyzer was used to segment cancer areas (CAs) and cancer stroma and to identify tumor-infiltrating lymphocytes (TILs), tertiary lymphoid structures, fibroblasts, and endothelial cells (ECs) in the tumor tissue. We analyzed 143 NSCLC samples after resistance to EGFR-TKIs from two cohorts: (1) 89 patients treated with ICI monotherapy and (2) 54 patients from the ATTLAS phase III trial comparing atezolizumab plus bevacizumab, paclitaxel, and carboplatin (ABCP) versus pemetrexed plus carboplatin. RESULTS: Post-TKI samples showed reduced TILs in the CA (p=0.045) and increased ECs in the CA (p=0.005) compared with pre-TKI samples. These changes differed according to EGFR mutation subtype. Higher TILs in CA were associated with a better overall response rate (ORR) and progression-free survival (PFS). Similarly, higher EC levels in CA correlated with improved ORR and PFS. In the ATTLAS cohort, these factors were associated with clinical benefits from ABCP, with a significant association with TILs and a marginal association with ECs. CONCLUSION: Our findings suggest that EGFR-TKIs affect the immune landscape of patients with EGFR-mutated NSCLC. Higher TILs or ECs in the CA were significantly associated with a favorable response to subsequent ICI-based treatment. TRIAL REGISTRATION NUMBER: NCT03991403.

KM 提取结果

1 个 Figure · 3 个 KM 面板

进入结果中心
KM Figure3 个面板

Figure 5

Figure 5. Efficacy outcomes with ICI after acquired resistance to EGFR-TKI. ( A ) Progression-free survival with ICIs monotherapy according to the IP after acquired resistance to EGFR-TKI. ( B ) Proportion bar plot indicating best response according to the TILs on CA, and ECs on CA. ( C ) Forest plot of HR (dot) and 95% CI (arrow) for PFS and OS according to the baseline characteristics and variables inferred from AI-powered TME analyzer. ( D–E ) Progression-free survival comparison between the ABCP arm and the PC arm in patients with higher TILs on CA ( D ) or ECs on CA ( E ) following EGFR-TKI treatment in the ATTLAS cohort. ABCP, atezolizumab plus bevacizumab, paclitaxel, and carboplatin; CA, cancer area; CS, cancer stroma; EC, endothelial cell; ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor; Fibs, fibroblasts; ICI, immune-checkpoint inhibitor; IP, immune-phenotype; PC, pemetrexed plus carboplatin; PD, progressive disease; PD-L1, programmed death-ligand 1; PR, partial response; SD, stable disease; TIL, tumor-infiltrating lymphocyte; TKI, tyrosine kinase inhibitor; TLS, tertiary lymphoid structure; TPS, tumor proportion score.

A

Progression-free survival

Figure 5 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Figure 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
D

Progression-free survival

Figure 5 · Panel D

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel D 是同一 Figure 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
E

Progression-free survival

Figure 5 · Panel E

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel E 是同一 Figure 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线缺失:预期 2 条,实际恢复 1 条曲线 1:extreme jump曲线 1:extreme upward reversal曲线 2:extreme jump
查看结果
其他 Figure(4,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1. The scheme of AI-powered TME analyzer and the workflow of the current study. ( A ) Study flow diagram. ( B ) Landscape of AI-IP analysis. ( C ) Representative images of TME analyzer. ( D ) Alluvial plot presenting the comparison of the AI-IP and RNA expression-based TME subtype. ( E ) Proportional bar plot showing PD-L1 expression tumor proportion scores, according to immune phenotype. ABCP, atezolizumab plus bevacizumab, paclitaxel, and carboplatin; AI, artificial intelligence; AI-IP, artificial intelligence-powered immune-phenotype; CA, cancer area; CP, carboplatin plus paclitaxel; CS, cancer stroma; EGFR, epidermal growth factor receptor; IDP, immune-desert immune phenotype; IEP, immune-excluded immune phenotype; IIP, inflamed immune phenotype; PD-L1, programmed death-ligand 1; TIL, tumor-infiltrating lymphocyte; TKI, tyrosine kinase inhibitor; TME, tumor microenvironment; TPS, tumor proportion score.
非 KM Figure
Figure 2Figure 2. Transcriptomic characteristics of TME assessed by AI-powered spatial analysis. ( A–B ) Representative figure showing the spatial distribution of AI-powered inferred cells and their matched Xenium points from spatial transcriptomics data. Comparison between cell inference based on an AI-powered TME analyzer (upper panel) and gene expression data from spatial transcriptomics (lower panel; Xenium, 10x Genomics). Spatial transcriptomic data were downloaded from the 10x Genomics website ( https://www.10xgenomics.com/datasets/preview-data-ffpe-human-lung-cancer-with-xenium -multimodal-cell-segmentation-1-standard). (C–F) Volcano plots showing DEGs in the spatial transcriptomic data matched with AI-predicted cell types from H&E slides for tumor cells (C), lymphocytes (D), ECs (E), and Fibs (F). A paired H&E image and Xenium spatial transcriptomic dataset from a lung adenocarcinoma case were used, focusing on a panel of 377 tumor-related and TME-related genes. The X-axis represents the change in the cell fraction with transcript detection relative to other cell types. The cell fraction was defined as the fraction of AI-predicted cell types that expressed specific genes. The Y-axis represents the −log10(p value) calculated using Fisher’s exact test. (G) Correlation heatmap of the transcriptomics-based score and AI-powered TME analysis. (H) Scatter plots showing the correlation between transcriptomics-based scores and the AI-powered TME. AI, artificial intelligence; CA, cancer area; CAF, cancer-associated fibroblast; CS, cancer stroma; DEG, differentially expressed gene; EC, endothelial cell; Fib, fibroblast; ICR, immunological constant of rejection; TIL, tumor-infiltrating lymphocyte; TME, tumor microenvironment; TLS, tertiary lymphoid structure; VEGF, vascular endothelial growth factor.
非 KM Figure
Figure 3Figure 3. Dynamic change of TME after acquired resistance to EGFR-TKI. ( A ) Overall landscape assessed by AI-IP analysis. ( B ) Dynamic change of PD-L1 expression after resistance to EGFR-TKI. ( C ) Alluvial plot presenting the change of PD-L1 expression after resistance to EGFR TKI. ( D ) Alluvial plot presenting the change of AI-IPs comparing pre-EGFR-TKI and post-EGFR-TKI treatment samples. ( E ) Dynamic change of AI-powered TME analysis in patients after resistance to EGFR-TKI. ABCP, atezolizumab plus bevacizumab, paclitaxel, and carboplatin; AI, artificial intelligence; CA, cancer area; CP, carboplatin plus paclitaxel; CS, cancer stroma; EC, endothelial cell; EGFR, epidermal growth factor receptor; Fibs, fibroblasts; TIL, tumor-infiltrating lymphocyte; TKI, tyrosine kinase inhibitor; TLS, tertiary lymphoid structure; TPS, tumor proportion score.
非 KM Figure
Figure 4Figure 4. Dynamic change of TME according to the EGFR mutant type. Comparison analysis of pre-TKI and post-TKI TILs on CA and ECs on CA based on exon 21 L858R (A), exon 19 deletion (B), acquired T790M-positive (C), and acquired T790M-negative (D) status. P values were calculated using the Wilcoxon rank-sum test. CA, cancer area; EC, endothelial cell; EGFR, epidermal growth factor receptor; TIL, tumor-infiltrating lymphocytes.
非 KM Figure